{"database": "lobbying", "table": "lobbying_activities", "rows": [[1879672, "52c11390-1aee-4898-85c8-34ad27f6a9c5", "Q3", "AMERICAN CLINICAL LABORATORY ASSN", 1923, "AMERICAN CLINICAL LABORATORY ASSN", 2016, "third_quarter", "MED", "Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B;  H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; and H.R 4909, the National Defense Authorization Act for Fiscal Year 2017.", "Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", null, 199612, 0, 0, "2016-10-17T14:37:32.477000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1879672"], "units": {}, "query_ms": 67.22725101280957, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}